AR086514A1 - Metodo de tratamiento del cancer de pulmon de celulas no pequeñas, composicion, uso, envase - Google Patents
Metodo de tratamiento del cancer de pulmon de celulas no pequeñas, composicion, uso, envaseInfo
- Publication number
- AR086514A1 AR086514A1 ARP120101802A ARP120101802A AR086514A1 AR 086514 A1 AR086514 A1 AR 086514A1 AR P120101802 A ARP120101802 A AR P120101802A AR P120101802 A ARP120101802 A AR P120101802A AR 086514 A1 AR086514 A1 AR 086514A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleotides
- taxane
- treatment
- oligonucleotide
- human patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 238000004806 packaging method and process Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 6
- 125000003729 nucleotide group Chemical group 0.000 abstract 6
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 229940123237 Taxane Drugs 0.000 abstract 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 4
- 238000002512 chemotherapy Methods 0.000 abstract 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para el tratamiento de un paciente humano afectado de cáncer de pulmón que comprende administrar periódicamente al paciente humano una quimioterapia que comprende una cantidad de un taxano y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCTTCATCAT (SEQ ID Nº 1). El oligonucleótido anti-clusterina tiene un esqueleto fosforotioato en toda su extensión, presenta unidades de azúcares en los nucleótidos 1 - 4 y 18 - 21 con modificaciones 2’-O-metoxietilo, los nucleótidos 5 - 17 que son 2’ desoxinucleótidos, y tiene 5-metilcitosinas en los nucleótidos 1, 4 y 19.Reivindicación 2: El método de la reivindicación 1, en donde el taxano es paclitaxel. Reivindicación 8: El método de la reivindicación 7, en donde el taxano es docetaxel. Reivindicación 13: El método de cualquiera de las reivindicaciones de 1 a 12, en donde la quimioterapia comprende además una cantidad de un agente quimioterapéutico basado en platino. Reivindicación 45: Una composición para el tratamiento de un paciente humano que sufre de cáncer de pulmón de células no pequeñas no resecable, avanzado o metastásico, que comprende una quimioterapia que consiste de un taxano y, opcionalmente, un agente quimioterapéutico basado en platino; y un oligonucleótido anti-clusterina que presenta la secuencia CAGCAGCAGAGTCTTCATCAT (SEQ ID Nº 1), en donde el oligonucleótido anti-clusterina tiene un esqueleto fosforotioato en toda su extensión, tiene grupos de azúcar en los nucleótidos 1 - 4 y 18 - 21 que contienen modificaciones 2’-O-metoxietilo, tiene los nucleótidos 5 - 17 que son 2’ desoxinucleótidos, y tiene 5-metilcitosinas en los nucleótidos 1, 4 y 19.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487918P | 2011-05-19 | 2011-05-19 | |
| US201161493346P | 2011-06-03 | 2011-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086514A1 true AR086514A1 (es) | 2013-12-18 |
Family
ID=47177396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101802A AR086514A1 (es) | 2011-05-19 | 2012-05-21 | Metodo de tratamiento del cancer de pulmon de celulas no pequeñas, composicion, uso, envase |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130017272A1 (es) |
| EP (1) | EP2709673A4 (es) |
| JP (1) | JP2014520081A (es) |
| KR (1) | KR20140034838A (es) |
| CN (1) | CN103958681A (es) |
| AR (1) | AR086514A1 (es) |
| AU (1) | AU2012257487A1 (es) |
| CA (1) | CA2836676A1 (es) |
| CL (1) | CL2013003324A1 (es) |
| EA (1) | EA201391725A1 (es) |
| IL (1) | IL227720A0 (es) |
| MX (1) | MX2013013384A (es) |
| PE (1) | PE20140647A1 (es) |
| PH (1) | PH12013502402A1 (es) |
| SG (1) | SG194931A1 (es) |
| WO (1) | WO2012156817A2 (es) |
| ZA (1) | ZA201309254B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| KR20140038388A (ko) | 2011-03-15 | 2014-03-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용 |
| UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
| CA2900533A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Anti-clusterin monotherapy for cancer treatment |
| US20140275214A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Custirsen treatment with reduced toxicity |
| US20160324439A1 (en) * | 2015-05-06 | 2016-11-10 | Taiwan Textile Research Institute | Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same |
| US20180155429A1 (en) * | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| ES2752063T3 (es) * | 2015-05-29 | 2020-04-02 | Dynavax Tech Corp | Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| KR20190115505A (ko) | 2018-03-15 | 2019-10-14 | 특허법인 해담 | 기업 맞춤형 후속 개발 아이템 발굴 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| ES2307942T3 (es) * | 2002-01-17 | 2008-12-01 | The University Of British Columbia | Oligonucleotidos antisentido biespecificos que inhiben igfbp-2 e igfbp-5 y metodos de uso. |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2006029023A2 (en) * | 2004-09-02 | 2006-03-16 | Isis Pharmaceuticals, Inc. | Polymeric beads for oligonucleotide synthesis |
-
2012
- 2012-05-18 AU AU2012257487A patent/AU2012257487A1/en not_active Abandoned
- 2012-05-18 KR KR1020137033743A patent/KR20140034838A/ko not_active Withdrawn
- 2012-05-18 WO PCT/IB2012/001085 patent/WO2012156817A2/en not_active Ceased
- 2012-05-18 MX MX2013013384A patent/MX2013013384A/es not_active Application Discontinuation
- 2012-05-18 PE PE2013002522A patent/PE20140647A1/es not_active Application Discontinuation
- 2012-05-18 EP EP12786050.0A patent/EP2709673A4/en not_active Withdrawn
- 2012-05-18 CN CN201280030054.1A patent/CN103958681A/zh active Pending
- 2012-05-18 JP JP2014510898A patent/JP2014520081A/ja active Pending
- 2012-05-18 CA CA2836676A patent/CA2836676A1/en not_active Abandoned
- 2012-05-18 PH PH1/2013/502402A patent/PH12013502402A1/en unknown
- 2012-05-18 SG SG2013083951A patent/SG194931A1/en unknown
- 2012-05-18 EA EA201391725A patent/EA201391725A1/ru unknown
- 2012-05-18 US US13/475,780 patent/US20130017272A1/en not_active Abandoned
- 2012-05-21 AR ARP120101802A patent/AR086514A1/es not_active Application Discontinuation
-
2013
- 2013-09-16 IL IL227720A patent/IL227720A0/en unknown
- 2013-11-19 CL CL2013003324A patent/CL2013003324A1/es unknown
- 2013-12-09 ZA ZA2013/09254A patent/ZA201309254B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013003324A1 (es) | 2014-08-01 |
| SG194931A1 (en) | 2013-12-30 |
| IL227720A0 (en) | 2013-09-30 |
| KR20140034838A (ko) | 2014-03-20 |
| ZA201309254B (en) | 2015-05-27 |
| EP2709673A2 (en) | 2014-03-26 |
| CA2836676A1 (en) | 2012-11-22 |
| WO2012156817A2 (en) | 2012-11-22 |
| MX2013013384A (es) | 2014-06-11 |
| PE20140647A1 (es) | 2014-06-05 |
| WO2012156817A9 (en) | 2013-01-03 |
| EP2709673A4 (en) | 2014-12-17 |
| US20130017272A1 (en) | 2013-01-17 |
| JP2014520081A (ja) | 2014-08-21 |
| CN103958681A (zh) | 2014-07-30 |
| PH12013502402A1 (en) | 2014-01-13 |
| AU2012257487A1 (en) | 2014-01-16 |
| EA201391725A1 (ru) | 2014-05-30 |
| WO2012156817A3 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086514A1 (es) | Metodo de tratamiento del cancer de pulmon de celulas no pequeñas, composicion, uso, envase | |
| Chen et al. | P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2 | |
| Chakraborty et al. | The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer | |
| Garofalo et al. | miR221/222 in cancer: their role in tumor progression and response to therapy | |
| Krützfeldt | Strategies to use microRNAs as therapeutic targets | |
| Park et al. | Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma | |
| Wang et al. | Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem‑like cells via induction of lncRNA HOTAIR | |
| AR091090A1 (es) | Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| Wang et al. | The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells | |
| Drayton | The role of microRNA in the response to cisplatin treatment. | |
| CN102140468A (zh) | 人miR-185*反义核酸及其应用 | |
| AR095416A1 (es) | Tratamiento con cutirsen que presenta una toxicidad reducida | |
| CN102533755A (zh) | 人miR-328反义核酸及其应用 | |
| Sun et al. | Epithelial-Mesenchymal transition and its regulation in tumor metastasis | |
| CN102140465B (zh) | 人miR-1249反义核酸及其应用 | |
| CN102140469A (zh) | 人miR-1233反义核酸及其应用 | |
| CN102643811B (zh) | 人miR-1229的反义寡聚核苷酸及其应用 | |
| Fuessel et al. | Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma | |
| Wahidur Rahman et al. | The therapeutic value of natural agents to treat miRNA targeted breast cancer in African-American and Caucasian-American women | |
| CN102140470B (zh) | 人miR-1236反义核酸及其应用 | |
| CN102643807B (zh) | 人miR-484的反义寡聚核苷酸及其应用 | |
| CN102140464B (zh) | 人miR-1238反义核酸及其应用 | |
| CN102643809B (zh) | 人miR-1274b的反义寡聚核苷酸及其应用 | |
| CN102643813B (zh) | 人miR-504的反义寡聚核苷酸及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |